Dicerna Pharma (DRNA) Tops Q1 EPS by 8c

Dicerna Pharma (NASDAQ: DRNA) reported Q1 EPS of ($0.30), $0.08 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.87 million.

For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.

You May Also Be Interested In

• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• VNET Group (VNET) Misses Q2 EPS by 164c
• Amer Sports, Inc. (AS) Tops Q2 EPS by 11c; raises guidance